Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC2-01 Cream in Adolescents with Extensive Psoriasis Vulgaris
NCT03819218Phase 2Terminated
- Sponsor
- MC2 Therapeutics
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of calcipotriol + betamethasone in Psoriasis vulgaris (PV), sponsored by MC2 Therapeutics. Primary endpoints: Number of Participants With HPA Axis Suppression at 8 weeks, Change in S-Calcium Metabolism at 8 weeks and 1 more. Started Dec 2018; status: terminated.
02
Drugs
calcipotriol + betamethasone
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT03819218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819218.